Atavistik Bio has dosed the first subject in its Phase I clinical trial of ATV-1601, designed to treat adults with solid tumours.

Spine BioPharma's Phase III MODEL trial assessing SB-01 for people with CLBP associated with DDD failed to achieve its primary goal.

Hansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with Duchenne muscular dystrophy (DMD) with Sarepta and Roche’s Elevidys ...

Eli Lilly's Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).

AbbVie has reported topline outcomes from the first of two trials of the Phase III UP-AA programme, assessing Rinvoq (upadacitinib).

Anavex's blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Lantern Pharma has completed targeted enrolment for its multi-centre Phase II HARMONIC trial of a disulfide small molecule, LP-300.

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Recognify Life Sciences has reported that its Phase IIb trial of inidascamine to treat CIAS failed to achieve its primary goal.

Shares in Celcuity climbed by 233.76% at market open on 28 July after it reported the Phase III breast cancer data.